Drug Trial Radar · NCT05935176
Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
660
Actual
Start
Sep 20, 2023
Primary completion
May 15, 2026
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- CanSino Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 23 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the immunogenicity and immunopersistence of the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector).The protocol consists of two parts: Part 1 enrolled 660 eligible participants aged 6 to 23 months, which has now been completed. Part 2 : Open Clinical Researchplans to enroll approximately 100 eligible participants from Part 1 who have completed immunopreservance blood sampling. Participants will receive a single booster dose of the ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) at age 3 years (but not yet 4 years).
Conditions
- Epidemic Meningitis
Interventions
MCV4Biological
2 dose of MCV4 on Day 0 and Month 1
MCV4Biological
2 dose of MCV4 on Day 0 and Month 3
MCV4Biological
1 booster dose of MCV4 at 3 years old
Primary outcomes
What the sponsor says the trial is designed to measure.
- Antibody positivity for A, C, Y and W135 in all subjects 6 months after 2 dose exemptionTime frame: 6 months after 2 dose exemption
- Seroconversion rates for serotypes A, C, Y, and W135Time frame: 30 days post-booster vaccination
- Geometric mean titers (GMTs) for serotypes A, C, Y, and W135Time frame: 30 days post-booster vaccination
- Increased incidence of adverse reactionsTime frame: Within 7 days after post-booster vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wuzhi County Center for Disease Control and Prevention
Jiaozuo, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.